REBACIN作为持续性高危人乳头瘤病毒感染非侵入性干预的有效性与安全性:一项真实世界前瞻性多中心队列研究
这项前瞻性多中心队列研究纳入3252例REBACIN组和249例对照组患者,评估REBACIN清除持续性高危人乳头瘤病毒(hrHPV)感染的安全性与有效性。REBACIN组清除率为60.64%,对照组为20.08%。HPV16/18单一型感染清除率高于HPV52/58,单一型感染清除率高于多重感染,年轻患者清除率高于年长患者,未发现严重不良反应。
要点
- REBACIN组持续性hrHPV清除率为60.64%,对照组为20.08%。
- HPV16单一型清除率70.62%、HPV18单一型69.23%,高于HPV52的59.04%和HPV58的62.64%。
- 单一、双重、三重/三重以上感染清除率分别为65.70%、53.31%、38.30%。
核心结论
- 本研究证实REBACIN可有效且安全地清除持续性hrHPV感染,HPV16/18清除率高于HPV52/58,单一型感染清除率高于多重感染,年轻患者清除率高于年长患者。
研究设计与样本
- 前瞻性多中心队列研究,按纳入/排除标准及受试者意愿分为REBACIN组3252例和对照组249例。
- REBACIN组接受一个疗程阴道给药REBACIN,对照组不治疗,停药后两组均随访。
主要发现
- REBACIN组持续性hrHPV感染清除率为60.64%,对照组为20.08%。
- HPV16单一型感染清除率为70.62%,HPV18单一型为69.23%,均高于HPV52的59.04%和HPV58的62.64%。
- 单一、双重、三重/三重以上感染清除率分别为65.70%、53.31%、38.30%。
- 40岁以下1635例患者清除率为65.14%,40岁以上1447例患者为55.08%。
- 未发现严重不良反应。
临床怎么用
- 作者认为本研究结果为真实世界环境下应用REBACIN清除持续性hrHPV感染提供了指导。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported that REBACIN effectively eliminates persistent high-risk human papillomavirus (hrHPV) infection. Here, we conducted a prospective multicenter cohort study to evaluate the safety and effectiveness of REBACIN, taking into account factors such as specific hrHPV subtype and patient's age. METHODS: According to inclusion/exclusion criteria and participant willingness, 3252 patients were divided into REBACIN group while 249 patients into control group. Patients in REBACIN group received one course treatment of intravaginal administration of REBACIN while no treatment in control group. After drug withdrawal, participants in both groups were followed up. RESULTS: The clearance rate of persistent hrHPV infection in REBACIN group was 60.64%, compared to 20.08% in control group. Specifically, the clearance rates for single-type infection of HPV16 or HPV18 were 70.62% and 69.23%, respectively, which was higher than that of HPV52 (59.04%) or HPV58 (62.64%). In addition, the single, double, and triple/triple+ infections had a clearance rate of 65.70%, 53.31%, and 38.30%, respectively. Moreover, 1635 patients under 40 years old had a clearance rate of 65.14%, while it was 55.08% for 1447 patients over 40 years old. No serious adverse effects were found. CONCLUSION: This study confirmed that REBACIN can effectively and safely eliminate persistent hrHPV infection, which the clearance rate of HPV16/18 is higher than that of HPV52/58, the clearance rate of single-type infection is higher than that of multiple-type infections, and the clearance rate in young patients is higher than that in elder patients, providing a guidance for REBACIN application in clearing hrHPV persistent infection in real-world settings. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry Registration Number: ChiCTR1800015617 http://www.chictr.org.cn/showproj.aspx?proj=26529 Date of Registration: 2018-04-11.
引用
- Chen F, Zhang GN, Lei W, et al. Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study. Gynecol Oncol. 2023. PMID: 37734188. doi:10.1016/j.ygyno.2023.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。